SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its novel echinocandin antifungal CD101 will be presented at two upcoming, major medical meetings. CD101 abstracts have been accepted for presentation at both ASM Microbe 2017 in New Orleans, Louisiana from June 1-5 and at the 22nd Annual Congress of the European Hematology Association (EHA) in Madrid, Spain from June 22-25. ASM Microbe 2017 will also feature a presentation of a study evaluating the real-world utilization of echinocandins in hospitalized patients with invasive fungal infections, providing insight into the unmet need for a novel echinocandin.
“These presentations highlight the potential of our novel echinocandin CD101 to treat and prevent a broad range of deadly fungal infections in critically ill patients where unmet needs exist,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Especially for those patients with hematologic diseases or for those undergoing transplantation, CD101 could significantly simplify antifungal prophylaxis regimens versus currently available options, which tend to complicate care due to drug-drug interactions, toxicities and resistance.”
Approximately 97,000 Americans die from hospital-related fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. Pneumocystis Pneumonia (PCP) is another serious fungal infection that commonly afflicts people with weakened immune systems. Systemic fungal infections typically affect patients whose immune systems have been compromised, such as patients undergoing organ or bone marrow transplantation or chemotherapy, including patients with hematologic malignancies, or patients in intensive care units and those with prolonged hospital stays.
Details of the Cidara ASM Microbe 2017 and the EHA Congress presentations are as follows:
ASM Microbe 2017 Poster Presentations
Title: Real-world Use of Echinocandins in an Era of Increasing
Antifungal Resistance; A.K. Sofjan, et. al.
Date and time: Friday, June 2 from 12:45 p.m. – 2:45 p.m. CDT
Location: Ernest N. Morial Convention Center, Exhibit Hall D
Presentation number: Friday-245
Session: Session 046 – AAID09 – Mycology: Clinical and Laboratory Studies of Antifungal Drug Resistance
Title: A Single-Dose, Subcutaneous (SC) Prophylaxis CD101
Administration Prevents Fungal Infection in Mouse Models of Candidiasis
and Aspergillosis; V. Ong, et. al.
Date and Time: Saturday, June 3 from 12:15 p.m. – 2:15 p.m. CDT
Location: Ernest N. Morial Convention Center, Exhibit Hall D
Presentation number: Saturday-241
Session: Session 195 – AAID09 – Mycology: New Antifungal Agents I
EHA Poster Presentation
Title: Antifungal Prophylaxis with CD101 in Immunosuppressed
Mouse Models of Candidiasis, Aspergillosis, and Pneumocystis
Pneumonia (PCP); V. Ong, et. al.
Date and time: Saturday, June 24 from 5:30 p.m. – 7:00 p.m. CEST
Location: IFEMA – Feria de Madrid, Poster area/Hall 7
Abstract number: P645
Session: Infectious Diseases, Supportive Care
Copies of all of these poster presentations will be available on the Cidara website following the meetings: www.cidara.com.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara recently received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, and other attributes of CD101, including the potential for these compounds to successfully treat and prevent fungal infections and simplify prophylaxis compared to current antifungal agents. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.